Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）	Acute Severe Ulcerative Colitis	Recruiting	Phase 4	2026-04-24		NCT07550673

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Xijing Hospital of Digestive Diseases	22

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
3201 Hospital	Hanzhong	China	2
Ankang Central Hospital	Ankang	China	2
Shaanxi Provincial Nuclear Industry 215 Hospital	Xianyang	China	1
Xijing Hosipital of Digestive Disease	Xi'an	China	1

Clinical trials